FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204291278> ?p ?o ?g. }

• W3204291278 abstract "Abstract Background This pairwise meta-analysis determines the difference in bleeding risks associated with the use of novel oral anticoagulants (NOACs) and aspirin. Methods PubMed, the Cochrane Library database, clinicaltrial.gov , and related studies were searched for randomized control trials (RCTs) comparing NOAC and aspirin published between January 1, 2000 and May 10, 2021. The primary endpoint was intracranial hemorrhage (ICH). Results Eleven studies involving 57,645 patients were included. Compared to aspirin, rivaroxaban (5 mg/day) had a similar risk of ICH, major bleeding, and fatal bleeding; rivaroxaban (10 mg/day) had higher risks of gastrointestinal hemorrhage (OR: 1.41; 95% CI: 1.03–1.94; P = 0.032; I 2 = 0%) and a similar risk of ICH, major bleeding, and fatal bleeding; and rivaroxaban (15–20 mg/day) had higher risks of ICH (OR: 3.21; 95% CI: 1.36–7.60; P = 0.008; I 2 = 0%), major bleeding (OR: 2.64; 95% CI: 1.68–4.16; P < 0.001; I 2 = 0%), and fatal bleeding (OR: 2.26; 95% CI: 1.25–4.08; P = 0.007; I 2 = 0%) and a similar risk of gastrointestinal hemorrhage. Bleeding outcomes between other NOACs (apixaban and dabigatran etexilate) and aspirin were not different. Conclusions The bleeding risks associated with NOACs depend on drug type and dosage. For ≥15 mg/day of rivaroxaban, the risk of ICH was significantly higher than that with aspirin. However, further studies comparing dabigatran etexilate and apixaban versus aspirin are warranted to draw a definite conclusion." @default.
• W3204291278 created "2021-10-11" @default.
• W3204291278 creator A5028277128 @default.
• W3204291278 creator A5028655134 @default.
• W3204291278 creator A5028836118 @default.
• W3204291278 creator A5041512622 @default.
• W3204291278 creator A5080780367 @default.
• W3204291278 creator A5080829158 @default.
• W3204291278 date "2021-10-02" @default.
• W3204291278 modified "2023-10-16" @default.
• W3204291278 title "Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis" @default.
• W3204291278 cites W1973068188 @default.
• W3204291278 cites W2083482655 @default.
• W3204291278 cites W2091049047 @default.
• W3204291278 cites W2098923148 @default.
• W3204291278 cites W2107328434 @default.
• W3204291278 cites W2125435699 @default.
• W3204291278 cites W2134833483 @default.
• W3204291278 cites W2149388786 @default.
• W3204291278 cites W2152623033 @default.
• W3204291278 cites W2157823046 @default.
• W3204291278 cites W2159927405 @default.
• W3204291278 cites W2557845780 @default.
• W3204291278 cites W2595086780 @default.
• W3204291278 cites W2596358769 @default.
• W3204291278 cites W2749380187 @default.
• W3204291278 cites W2752033985 @default.
• W3204291278 cites W2788601536 @default.
• W3204291278 cites W2790180402 @default.
• W3204291278 cites W2803966697 @default.
• W3204291278 cites W2885720285 @default.
• W3204291278 cites W2945825099 @default.
• W3204291278 cites W2957544571 @default.
• W3204291278 cites W2987620153 @default.
• W3204291278 cites W2989714602 @default.
• W3204291278 cites W3010591211 @default.
• W3204291278 cites W3011371150 @default.
• W3204291278 cites W3024224644 @default.
• W3204291278 cites W3034070838 @default.
• W3204291278 cites W3082188176 @default.
• W3204291278 cites W3090209681 @default.
• W3204291278 cites W3120804397 @default.
• W3204291278 cites W4229536675 @default.
• W3204291278 doi "https://doi.org/10.1186/s12959-021-00322-6" @default.
• W3204291278 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8487538" @default.
• W3204291278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34600549" @default.
• W3204291278 hasPublicationYear "2021" @default.
• W3204291278 type Work @default.
• W3204291278 sameAs 3204291278 @default.
• W3204291278 citedByCount "2" @default.
• W3204291278 countsByYear W32042912782023 @default.
• W3204291278 crossrefType "journal-article" @default.
• W3204291278 hasAuthorship W3204291278A5028277128 @default.
• W3204291278 hasAuthorship W3204291278A5028655134 @default.
• W3204291278 hasAuthorship W3204291278A5028836118 @default.
• W3204291278 hasAuthorship W3204291278A5041512622 @default.
• W3204291278 hasAuthorship W3204291278A5080780367 @default.
• W3204291278 hasAuthorship W3204291278A5080829158 @default.
• W3204291278 hasBestOaLocation W32042912781 @default.
• W3204291278 hasConcept C121608353 @default.
• W3204291278 hasConcept C126322002 @default.
• W3204291278 hasConcept C168563851 @default.
• W3204291278 hasConcept C2776301958 @default.
• W3204291278 hasConcept C2776478404 @default.
• W3204291278 hasConcept C2777628954 @default.
• W3204291278 hasConcept C2778080469 @default.
• W3204291278 hasConcept C2778435480 @default.
• W3204291278 hasConcept C2778661090 @default.
• W3204291278 hasConcept C2778810321 @default.
• W3204291278 hasConcept C2779161974 @default.
• W3204291278 hasConcept C2780638905 @default.
• W3204291278 hasConcept C42219234 @default.
• W3204291278 hasConcept C526805850 @default.
• W3204291278 hasConcept C71924100 @default.
• W3204291278 hasConcept C90924648 @default.
• W3204291278 hasConceptScore W3204291278C121608353 @default.
• W3204291278 hasConceptScore W3204291278C126322002 @default.
• W3204291278 hasConceptScore W3204291278C168563851 @default.
• W3204291278 hasConceptScore W3204291278C2776301958 @default.
• W3204291278 hasConceptScore W3204291278C2776478404 @default.
• W3204291278 hasConceptScore W3204291278C2777628954 @default.
• W3204291278 hasConceptScore W3204291278C2778080469 @default.
• W3204291278 hasConceptScore W3204291278C2778435480 @default.
• W3204291278 hasConceptScore W3204291278C2778661090 @default.
• W3204291278 hasConceptScore W3204291278C2778810321 @default.
• W3204291278 hasConceptScore W3204291278C2779161974 @default.
• W3204291278 hasConceptScore W3204291278C2780638905 @default.
• W3204291278 hasConceptScore W3204291278C42219234 @default.
• W3204291278 hasConceptScore W3204291278C526805850 @default.
• W3204291278 hasConceptScore W3204291278C71924100 @default.
• W3204291278 hasConceptScore W3204291278C90924648 @default.
• W3204291278 hasIssue "1" @default.
• W3204291278 hasLocation W32042912781 @default.
• W3204291278 hasLocation W32042912782 @default.
• W3204291278 hasLocation W32042912783 @default.
• W3204291278 hasLocation W32042912784 @default.
• W3204291278 hasOpenAccess W3204291278 @default.
• W3204291278 hasPrimaryLocation W32042912781 @default.
• W3204291278 hasRelatedWork W1436836526 @default.
• W3204291278 hasRelatedWork W1975219299 @default.

• next